Inovio Pharmaceuticals Reports 2019 Second Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Inovio Pharma (INO) Misses Q2 EPS by 3c
August 8, 2019 5:53 PM EDTInovio Pharma (NASDAQ: INO) reported Q2 EPS of ($0.30), $0.03 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $135.67 thousand versus the consensus estimate of $5.66 million.
Dr. J. Joseph Kim, Inovio's President & CEO said, "Inovio is well-positioned to advance its... More
